Andrew Fariello, ’95, to keynote ceremony welcoming the Class of 2029

The MUSC College of Pharmacy’s 2025 White Coat Ceremony, held August 15, 2025, in Room 110 of the Drug Discovery Building on the MUSC campus, will feature keynote speaker Andrew Fariello, ’95.

Fariello just celebrated his 30^th reunion, having earned his Pharm.D. from the MUSC College of Pharmacy in 1995. Currently vice president of global medical affairs, head medical excellence oncology for AstraZeneca, he joined MUSC from St. John’s University, where he earned a BS in pharmacy in 1989 and then an MS in pharmacy in 1992. While a student, he worked in a pharmacy at St. John’s Queen’s Hospital and then, from 1991-1993, as an oncology pharmacist at Long Island Jewish Medical Center.

After graduation, he joined All Children’s Hospital in St. Petersburg, Florida as a clinical pharmacist, where among other duties he developed the clinical pharmacy service for pediatric intensive care and administered clinical trial programs.

In 2000, he joined AstraZeneca Pharmaceuticals and has been an upward path through the pharmaceutical giant ever since.

For the next 13 years, he served in sequential roles as medical science liaison, regional director of scientific affairs and then as senior director of medical affairs. In this last position, he led HQ and field medical affairs teams for multiple disease states and was responsible for the development and execution of medical affairs brand strategy.

Promoted to AstraZeneca, the global parent company, in 2014, he served as vice president for US Medical Affairs out of Wilmington, Delaware, then as head of global medical capabilities, oncology business unit, and then as vice president of global medical capabilities, oncology out of Gaithersburg, Maryland. Since 2020, he has served as vice president of global medical affairs, head medical excellence oncology.

His industry career has given him experience in leading medical affairs teams through product launches, developing medical strategy, fostering strong key opinion leader relationships, and bridging scientific expertise with business acumen.